文献速递心力衰竭与心肌病

慢性射血分数降低心衰一线药物联合方案的成本效果分析

Model-based cost-effectiveness analysis of first-line pharmacotherapy combinations in adults with chronic heart failure and reduced ejection fraction.
PubMed 文献 · Heart · 2026-03-11

本研究从英格兰NHS视角构建终身队列马尔可夫模型,评估五种一线药物联合方案治疗慢性HFrEF的成本效果。

要点

  • 能耐受ACEI的HFrEF患者,一线ACEI+BB+MRA+SGLT2i的ICER为£7699,最具成本效果。
  • 一线四联药物方案相比逐步加药策略具有成本效果,支持早期启动四联治疗。

核心结论

  • 一线四联药物联合方案相比逐步加药策略治疗HFrEF具有成本效果,早期启动四联治疗可能改善健康结局并优化医疗资源利用。

研究设计与样本

  • 从英格兰NHS视角构建终身队列马尔可夫模型,评估五种一线药物联合方案的成本效果。
  • 基线住院率和死亡率来自真实世界数据,治疗效应(HR)来自随机对照试验综述。

主要发现

  • 上述结果主要由ARNI相比ARB带来更大的相对QALY增益所驱动。

临床怎么用

  • 对能耐受ACEI的HFrEF患者,可优先考虑一线启动ACEI+BB+MRA+SGLT2i四联方案。
  • 对不能耐受ACEI的HFrEF患者,可优先考虑一线启动ARNI+BB+MRA+SGLT2i四联方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pharmacotherapy combinations have been shown to improve survival and reduce hospitalisations in adults with chronic heart failure with reduced ejection fraction (HFrEF); however, their cost-effectiveness when used as first-line treatment remains uncertain. METHODS: A lifetime cohort Markov model was developed from the perspective of the NHS in England to assess the cost-effectiveness of five first-line pharmacotherapy combinations: (i) angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) and beta-blocker (BB) (NICE-recommended treatment at the time of analysis); (ii) ACEI/ARB, BB and mineralocorticoid receptor antagonists (MRA); (iii) angiotensin receptor-neprilysin inhibitor (ARNI), BB and MRA; (iv) ACEI/ARB, BB, MRA and sodium-glucose cotransporter-2 inhibitor (SGLT2i); and (v) ARNI, BB, MRA and SGLT2i. Baseline hospitalisation and mortality rates were informed by real-world data, while treatment effects (HRs) were derived from a review of randomised controlled trials. RESULTS: Among individuals able to tolerate an ACEI, the combination of ACEI, BB, MRA and SGLT2i (cost, £12 124; quality-adjusted life years (QALYs), 5.72) was found to be the most cost-effective first-line treatment option with an incremental cost-effectiveness ratio (ICER) of £7699.Among individuals unable to tolerate an ACEI, the combination of ARNI, BB, MRA and SGLT2i (cost, £18 950; QALYs, 6.04) was found to be the most cost-effective first-line treatment option with an ICER of £15 821. The next most cost-effective first-line treatment option was the combination of ARB, BB, MRA and SGLT2i (cost, £11 842; QALYs, 5.59). These findings were primarily driven by the greater relative QALY gain of ARNI compared with ARB. CONCLUSIONS: This study demonstrates that a first-line quadruple pharmacotherapy combination is cost-effective compared with a stepwise approach for treating people with HFrEF, suggesting that wider adoption of early initiation of quadruple pharmacotherapy may improve health outcomes and optimise healthcare resource use.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Mariani, Luckham, Miles, et al. Model-based cost-effectiveness analysis of first-line pharmacotherapy combinations in adults with chronic heart failure and reduced ejection fraction. Heart. 2026. PMID: 41813099. doi:10.1136/heartjnl-2025-327190

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。